The Urology Group Surpasses 1,600 Prostate Cancer Patients Treated with the Accuray CyberKnife® M6™ System
One key step men can take to improve their health is to speak with their physician about whether a prostate-specific antigen (
- Eat no less than 2½ cups of a wide variety of fruits and vegetables every day
- Be physically active
- Maintain a healthy weight
"For more than 20 years,
The prostate gland can move unpredictably throughout the course of treatment, making the ability to track, detect and correct for motion critically important. In fact, the prostate has been documented to move as much as 10 mm in as little as 30 seconds due to normal patient bodily functions such as filling of the bladder, gas in the bowel or even slight patient movement during the procedure. The CyberKnife System's ability to automatically stay on target despite patient and tumor motion is what differentiates it from other types of radiation therapy delivery systems. With true motion synchronization, it tracks the tumor continually throughout the treatment session so that it can more accurately deliver radiation to where the tumor is, not where it used to be. CyberKnife SBRT is completed in 4-5 sessions instead of the 30-40 sessions usually required with conventional radiation therapy to safely spare normal tissues adjacent to the prostate, and is noninvasive (no surgery involved).
"A cancer diagnosis can be devastating and the journey to understand the disease and treatment options overwhelming," said Lionel Hadjadjeba, M.D., Senior Vice President and Chief Customer Experience Officer at
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, and patient experiences and outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to develop new products or enhance existing products to meet customers' needs, the company's ability to maintain or increase its gross margins on product sales and services, the company's ability to meet the covenants under its credit facilities, the company's ability to convert backlog to revenue and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director,
+1 (408) 789-4426
+1 (781) 684-6610
View original content to download multimedia:http://www.prnewswire.com/news-releases/the-urology-group-surpasses-1-600-prostate-cancer-patients-treated-with-the-accuray-cyberknife-m6-system-300779533.html